For some time now, catheter-based renal denervation therapy has been considered a transformative technology for reducing blood pressure in patients with uncontrolled or resistant hypertension. The Cardiovascular Research Foundation (New York) recognized the importance of this topic last fall when the organization dedicated a four-hour session during its annual Transcatheter Cardiovascular Therapeutics meeting (Medical Device Daily, Oct. 26, 2012).